Open AccessComparison of Different Loading Dose of Celecoxib on Postoperative Anti‐inflammation and Analgesia in Patients Undergoing Endoscopic Nasal Surgery—200 mg Is Equivalent to 400 mg
Author(s) -
Zhao Hong,
Feng Yi,
Wang Ying,
Yang Baxian,
Xing Zhimin
Publication year - 2011
Publication title -
pain medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 97
eISSN - 1526-4637
pISSN - 1526-2375
DOI - 10.1111/j.1526-4637.2011.01196.x
Subject(s) - medicine , celecoxib , anesthesia , inflammation , surgery , pharmacology
Objective. To demonstrate the efficacy and noninferiority of loading dose of celecoxib 200 mg compared with 400 mg in pain management after endoscopic nasal surgery. Design. A prospective randomized controlled study. Setting. A university hospital. Patients. Consecutive 120 patients undergoing endoscopic nasal surgery under general anesthesia were randomly assigned to three groups of 40 patients each, celecoxib 400 mg, celecoxib 200 mg, or a control group with no celecoxib. Interventions. Patients received different doses of celecoxib as described 1 hour before anesthesia. Two celecoxib groups received celecoxib 200 mg every 12 hours until the fifth day after surgery. Outcome Measures. Noninferiority could be claimed if the lower limit of the confidence interval (CI) for pain score difference was greater than −0.6. At 0, 6, and 48 hours after surgery, prostaglandin E 2 (PGE 2 ) and thromboxane A 2 (TXA 2 ) to prostaglandin I 2 (PGI 2 ) ratios were measured from incision drainage and in plasma. Results. Estimated difference between two loading doses for pain scores over 5 days was 0.275 (95%CI −0.255 to 0.805, P > 0.05), indicating the noninferiority of celecoxib 200–400 mg. Local PGE 2 at 6 hours and 48 hours positively correlated with pain scores, with correlation coefficients 0.371 ( P = 0.005) and 0.288 ( P = 0.033). Systemic TXA 2 to PGI 2 ratios did not differ among groups. Conclusions. An initial dose of celecoxib 200 mg was equivalent to celecoxib 400 mg with regard to the margin previously specified at −0.6 in reducing moderate postoperative pain in endoscopic nasal surgery both in analgesic efficacy and anti‐inflammatory property. One hundred and twenty patients were included in this prospective randomized controlled study. Patients treated with celecoxib had lower pain scores than controls, pain scores correlating with local PGE 2 level. An initial dose of celecoxib 200 mg was equivalent to 400 mg in reducing moderate pain after endoscopic nasal surgery.